BioLargo (BLGO) Q2 2026 earnings summary

Executive summary

• Revenue for the six months ended June 30, 2026, was $2.36 million, down 61% year-over-year due to the loss of a major private-label customer in 2025, but grew 12% sequentially in Q2 2026.

• Net loss for the six months was $7.41 million, with Q2 2026 net loss at $4 million, and Clyra Medical accounting for 59% of the Q2 loss.

• The company operates in cleantech, focusing on odor/VOC control, water treatment, battery energy storage, medical devices, and engineering services.

• Major product launches and relaunches are planned for the next six to nine months, including consumer products and medical devices.

Financial highlights

• Q2 2026 revenue was $1.25 million, up from $1.12 million in Q1 2026, but year-over-year revenue declined 55% due to the exit from Pooph-branded product sales.

• Gross margin improved to 54% in Q2 2026 from 51% in Q2 2025; gross profit for the six months was $1.13 million, down from $2.91 million year-over-year.

• Operating expenses rose to $8.06 million from $6.57 million, driven by higher R&D and SG&A.

• Net loss per share was $(0.02) for the six months, compared to $(0.008) in the prior year.

Outlook and guidance

• Management does not expect gross profits in 2026 to cover operational costs and anticipates the need for further investment capital.

• Consumer products relaunch set for October 2026 under a company-owned model, with anticipated milestones including new distributor orders and product launches.

• Substantial doubt exists about the company's ability to continue as a going concern without increased revenues or additional financing.